Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PASG
- Price
- 7.82
- Stock movement down
- -5.80 (-3.77%)
- Company name
- Passage Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 470.44M
- Ent value
- 477.19M
- Price/Sales
- 79.57
- Price/Book
- 6.47
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -97.47%
- 3 year return
- -79.66%
- 5 year return
- -73.53%
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PASG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 79.57 |
| Price to Book | 6.47 |
| EV to Sales | 80.71 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.18M |
| EPS (TTM) | -22.28 |
| FCF per share (TTM) | -19.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.91M |
| Gross profit (TTM) | 3.50M |
| Operating income (TTM) | -74.58M |
| Net income (TTM) | -68.80M |
| EPS (TTM) | -22.28 |
| EPS (1y forward) | -5.85 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 59.18% |
| Operating margin (TTM) | -1261.43% |
| Profit margin (TTM) | -1163.73% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 32.29M |
| Net receivables | 0.00 |
| Total current assets | 87.22M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 33.08M |
| Total assets | 111.75M |
| Accounts payable | 1.49M |
| Short/Current long term debt | 25.82M |
| Total current liabilities | 16.95M |
| Total liabilities | 39.04M |
| Shareholder's equity | 72.72M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -59.03M |
| Capital expenditures (TTM) | 33.00K |
| Free cash flow (TTM) | -59.06M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -94.61% |
| Return on Assets | -61.56% |
| Return on Invested Capital | -89.99% |
| Cash Return on Invested Capital | -77.26% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 154.00 |
| Daily high | 154.00 |
| Daily low | 146.06 |
| Daily Volume | 0K |
| All-time high | 288560.00 |
| 1y analyst estimate | 59.25 |
| Beta | 1.81 |
| EPS (TTM) | -22.28 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 18 Nov 2025 |
Downside potential
Loading...
Downside potential data
| PASG | S&P500 | |
| Current price drop from All-time high | -99.95% | -1.46% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 21 Jul 2025 | 9 Mar 2009 |
| Avg drop from high | -80.39% | -10.99% |
| Avg time to new high | 92 days | 12 days |
| Max time to new high | 1298 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
470.44M
Marketcap category
Small-cap
Description
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Employees
60
Website
Investor relations
-
SEC filings
CEO
Bruce A. Goldsmith
Country
USA
City
Philadelphia
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page